



Date: 14/08/2019.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".
Sub: Outcome of Board Meeting held on 14th August, 2019 & Submission of financial result.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 14th August, 2019 has considered and approved the following:

- Unaudited Standalone Financial result for the Quarter ended on 30th June 2019 along Limited Review Report.
- Pursuing and commencing business specified in main object clause no. 1a & 1b of trading and dealing in Agriculture products.

We wish to inform you that Board Meeting commenced today at 04.00 p.m. and concluded at 6.15 p.m.

We are enclosing herewith the copy of approved financial result.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited

Mr. Aakashkumar Keshari
Company Secretary

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.
• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com
CIN No.: L99999MH1993PLC072892

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


**Review Report
To,
The Board of Directors
Bajaj Healthcare Limited.**

1. We have reviewed the accompanying statement of unaudited financial results of Bajaj Healthcare Limited for the Quarter ended 30th June 2019, attached herewith being submitted by the Company pursuant to the requirement of regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulation 2015 read with SEBI circular CIR/CFD/FAC/62/2016 dated 5th July,2016 as amended ('the Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standard " prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Paresh Rakesh & Associates
Chartered Accountants
FRN: 119728W**



**Rakesh Chaturvedi
Partner
Membership. no 102075
UDIN: 19102075AAAAEI7111**



**Date: August 14, 2019
Place: Mumbai Thane**

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER YEAR ENDED ON 30TH JUNE, 2019

(Rs. In Lakhs)

Particulars	Quarter Ended	Six Months Ended		Year Ended
	30.06.2019	31.03.2019	30.09.2018	31.03.2019
	(UnAudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	9,169.38	18,110.80	18,906.57	37,017.37
II. Other Income	41.17	28.63	68.54	97.17
III. Total Revenue (I+II)	9,210.55	18,139.43	18,975.12	37,114.55
IV. Expenses				
(a) Cost of materials consumed (including Other Direct Expenses)	7,007.71	13,438.70	15,694.60	29,133.30
(b) Changes in Inventories of Finished Good	284.89	707.63	-1,037.82	-330.20
(c) Employee benefits expense	635.00	1,316.88	1,145.01	2,461.90
(d) Finance Costs	182.67	407.36	394.42	801.78
(d) Depreciation and amortisation expense	294.15	580.61	560.40	1,141.00
(e) Other expenses	344.25	297.22	1,192.56	1,489.79
Total Expenses	8,748.67	16,748.40	17,949.17	34,697.57
V. Profit before Exceptional and Extra Ordinary Items	461.88	1,391.03	1,025.94	2,416.98
VI. Exceptional items	-	-	-	-
VII. Profit before Extra Ordinary Items	461.88	1,391.03	1,025.94	2,416.98
VIII. Exceptional items	-	-	-	-
IX. Profit Before Tax	461.88	1,391.03	1,025.94	2,416.98
X. Tax Expense				
(a) Current tax	140.00	345.00	330.00	675.00
(b) Deffered Tax	-2.30	35.13	3.79	38.92
(c) Earlier Years	-	5.16	66.86	72.02
Total Tax Expenses	137.70	385.30	400.65	785.95
XI. Profit (Loss) from Continuing Operations	324.18	1,005.74	625.29	1,631.03
XII. Profit (Loss) from Discontinuing Operations	-	-	-	-
XIII. Profit (Loss) for the period (IX + X)	324.18	1,005.74	625.29	1,631.03
XIV. Paid-up Equity Share Capital (Face Value Rs. 10/-)	1,379.92	689.96	689.96	689.96
XV. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year		-	-	8198.25
XVI. EPS (Not Annualised)				
(a) Basic	2.35	7.29	4.53	11.82
(b) Diluted	2.35	7.29	4.53	11.82

- Note :
- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 14th August 2019
 - The Financial Account of the Company are prepared under Indian GAAP as the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019. Ind-AS will be applicable from 1st April 2020.
 - Comparative Figures for Quarters ended 30th June 2018 and 31st March 2019 are not provided, since the company was listed in SME segment until 31st March 2019 and was required to prepare & publish half yearly results instead of quaterly results upto 31st March 2019. Such, half yearly figures published are provided which are not Comparable.
 - The figures for the previous period have been regrouped whenever necessary.
 - The Statement as per Accounting Standard AS - 17 on segment reporting is given as Anneuxre A.
 - EPS has been calculated on 13799200 Equity Shares of Rs.10 each including Bonus Issue of 6899600 Fully paid up Equity Shares of Rs.10 each on April 11, 2019, consequently the EPS for previous reporting periods are adjusted accordingly.

For Bajaj Healthcare Ltd.

Director

DTN 00225950

Date: 14th August 2019
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 30TH JUNE , 2019

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended	Six Months Ended		Year Ended
		30.06.2019 (UnAudited)	31.03.2019 (Audited)	30.09.2018 (UnAudited)	31.03.2019 (Audited)
A	Segment Revenue (Excluding Intersegment Revenue)				
	Bulk Drugs	8674.87	17631.27	18524.04	36155.31
	Formulations	494.51	479.53	382.53	862.06
	Total	9,169.38	18,110.80	18,906.57	37,017.37
	Segment Revenue (Intersegment Revenue)				
	Bulk Drugs	563.34	297.78	378.63	676.41
	Formulations	31.06	33.22	51.88	85.10
	Total	594.40	331.00	430.50	761.51
	Gross Segment revenue (Including Intersegment Revenue)				
	Bulk Drugs	9238.21	17929.05	18902.67	36831.72
Formulations	525.58	512.76	434.41	947.17	
Total	9,763.78	18,441.80	19,337.08	37,778.88	
B	II. Segment Results				
	Profit / (Loss) Before Tax & Finance Cost				
	Bulk Drugs	1,088.10	2,222.18	2,734.43	4,956.61
	Formulations	-99.29	-126.56	-121.50	-248.06
	Total	988.80	2,095.62	2,612.93	4,708.55
	Less : Interest	182.67	407.36	394.42	801.78
Other Unallocable Expenditure (Net)	344.25	297.22	1,192.56	1,489.79	
Net of Unallocable Income	-	-	-	-	
Total Profit Before Tax	461.88	1,391.03	1,025.94	2,416.98	
C	I. Segment Assets				
	Bulk Drugs	25,008.11	25,099.65	26,014.71	25,099.65
	Formulations	1,967.82	1,584.80	1,608.04	1,584.80
	Others	500.31	0.31	0.31	0.31
	Total	27,476.24	26,684.76	27,623.05	26,684.76
	II. Segment Liabilities				
	Bulk Drugs	12,552.71	12,466.14	14,769.99	12,466.14
	Formulations	582.17	331.64	283.16	331.64
	Others	1,106.53	976.33	664.91	976.33
	Total	14,241.41	13,774.11	15,718.06	13,774.11
	III. Capital Employed				
	Total Capital Employed	13,234.83	12,910.64	11,904.99	12,910.64
	Total (II+III)	27,476.24	26,684.76	27,623.05	26,684.76

For Bajaj Healthcare Ltd.



Director

DIN 00225950

Place : Thane
Date: 14th August 2019